In 1996, Dr. Arul M. Chinnaiyan and Dr. Kenneth J. Pienta started this program with the goals of advancing medicine and benefiting patients. We strive to achieve those goals today.
Spirit of the Program
Molecular study of metastatic cancers is difficult because most patients with widely disseminated disease never undergo tumor resection. There is a need for high-quality tumor samples from patients with advanced cancers. Rapid autopsies are performed within 3 hours of death to allow:
The Michigan Legacy Tissue Program (MLTP) is dedicated to the patients and their families for their unconditional contribution to further the cause of medicine and to advance cutting-edge cancer research. Donor tissues are investigated by diverse platforms including next-generation sequencing and utilized to develop and validate new diagnostic and therapeutic markers in diverse malignancies. This program facilitates clinical translation of emerging molecular advances in an efficient, accurate and expeditious manner. Above all, even after death, patients and their families can make a lasting impact in the lives of future patients, giving others a better chance at life by participating in groundbreaking clinical cancer research.